Skip to content

EIGER BIOPHARMACEUTICALS, INC.

CIK 0001305253

← back to feed
Revenue (TTM)
$15.97M
+17.0% YoY FY Apr 2024
Net Income (TTM)
−$88.62M
+22.5% YoY FY Apr 2024
EPS Diluted (TTM)
−$2.02
+27.2% YoY FY Apr 2024
Gross Margin
89.9%
FY Apr 2024
Operating Margin
-535.7%
FY Apr 2024
Net Margin
-555.0%
FY Apr 2024
Free Cash Flow (TTM)
−$75.39M
FY Apr 2024
Cash
$25.44M
FY Apr 2024
Total Debt
$41.12M
FY Apr 2024
Shares Outstanding
1.48M sh
FY Apr 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings